Jiangsu Vcare Closes Series A2 Financing
Published Time:
2022-05-06 17:26
Source:
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series A2 financing round. This marks the successful closing of the company’s Series A financing, bringing the total Series A funding to nearly $60 million. This round was led by existing investor SDIC Capital, with co-investment from Yangtze River Industry Group. The proceeds will primarily support the R&D of innovative drug candidates as well as the construction of R&D and production bases for its CDMO business.
Currently, Jiangsu Vcare’s innovative drug pipeline is advancing steadily, with multiple drug candidates progressing through key stages. In 2022, several programs reached critical milestones:Vicagrel, a new cardiovascular and cerebrovascular drug (targeting P2Y12), obtained clinical approval from the US FDA. The drug has already initiated Phase III clinical research in China, with a research protocol that meets the requirements for both Chinese and US filings, and the US clinical trial is about to start; VC004, an anti-tumor new drug (targeting NTRK), has enrolled multiple patients in its Ib trial with significant efficacy, and the US IND application is soon to be submitted; VC005, a highly selective JAK1 inhibitor, is about to complete the SAD study, showing favorable preliminary safety and PK-PD properties. Additionally, nearly ten innovative drug candidates are in active development. The company’s wholly-owned subsidiary, Nanjing Vcare Pharmatech Co., Ltd. , continues to enhance its integrated CRO/CDMO services. Its Phase II CDMO R&D Technology Center is nearing completion, and the acquisition and construction of CDMO manufacturing facilities are progressing rapidly. With investor support, Jiangsu Vcare will accelerate its dual-track strategy: advancing proprietary drug development while expanding comprehensive drug industry chain services.
Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: "We are honored by the continued trust of our existing shareholders and deeply grateful for the recognition from new investors. Together, we will integrate resources to empower Vcare’s growth, accelerating the development of our integrated CRO/CDMO platform. We are proud to contribute our team’s decades of industry expertise, innovative technologies, internationally compliant manufacturing controls, and commitment to green chemistry principles to China’s dynamic and innovative pharmaceutical sector. This collaboration will strengthen China’s pharmaceutical supply chain, accelerate global integration, and deliver sustainable long-term value for our shareholders."
Related News
28
2025
/
04
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the successful enrollment of the first participant in its Phase II clinical trial for VC005 topical gel, a self-developed next-generation highly selective JAK1 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD). The trial aims to evaluate the efficacy of VC005 gel in adult patients with mild-to-moderate AD, providing a critical data for dose selection in future clinical studies and further assesses the drug's safety profile.
View Details
11
2025
/
04
Recently, following joint review by Nanjing Jiangbei New Area Sci-Tech Bureau and Nanjing Municipal Science and Technology Bureau, the"Nanjing Key Laboratory for Artificial Intelligence (AI) Drug Design"established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) was approved as a 2025 Nanjing Key Laboratory. This marks authoritative recognition of Jiangsu Vcare’s scientific capabilities, with the Lab having achieved significant progress in drug design and molecular discovery.
View Details
26
2025
/
03
Jiangsu Vcare Launches Phase II Trial for VC005 Topical Gel in Mild-to-Moderate Atopic Dermatitis
On March 26, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) officially launched the Phase II clinical trial for its self-developed, highly selective JAK1 inhibitor VC005 gel for the topical treatment of mild-to-moderate atopic dermatitis (AD). The completed Phase I clinical study of VC005 gel demonstrated excellent safety and significant efficacy.
View Details
27
2025
/
01
Jiangsu Vcare Honored As: National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises; Top 100 China Pharma Innovation Seed Enterprises; Jiangsu Listed Sci-Tech Enterprise Cultivation Program; Jiangsu Chemical Innovative Drug Engineering Research Center; Top 500 China Hidden Unicorn Enterprises
View Details
26
2025
/
01
In January 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that its self-developed next-generation anti-resistant TRK inhibitor VC004 capsule has officially entered the domestic NDA preparation phase, initiating pre-NDA communications with regulatory authorities. Marking this milestone, Jiangsu Vcare has joined the top tier of domestic self-developed drugs targeting this pathway at remarkable speed.
View Details
22
2025
/
01
Jiangsu Vcare Secures Nearly CNY 200 Million in Series C+ Financing
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C+ financing round, raising nearly CNY 200 million. The round was jointly invested by Xinghe Venture Capital, Jinlong Investment, SDIC Capital, and Yangtze River Industry Group. The proceeds will accelerate clinical advancement of Jiangsu Vcare’s innovative drug pipelines, strengthen its integrated CRO/CDMO service ecosystem, enhance independent innovation capabilities, and advance strategic initiatives in synthetic biology and green chemistry. This brings Jiangsu Vcare’s total equity financing to over CNY 1 billion, demonstrating sustained capital market confidence.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn